Classification of BRCA1 missense variants of unknown clinical significance

C M Phelan, V Dapić, B Tice, R Favis, E Kwan, F Barany, S Manoukian, P Radice, R B van der Luijt, B P M van Nesselrooij, G Chenevix-Trench, kConFab, T Caldes, M de La Hoya, S Lindquist, S V Tavtigian, D Goldgar, Å Borg, S A Narod, A A Monteiro

Background: BRCA1 is a tumour suppressor with pleiotropic actions. Germline mutations in BRCA1 are responsible for a large proportion of breast-ovarian cancer families. Several missense variants have been identified throughout the gene but because of lack of information about their impact on the function of BRCA1, predictive testing is not always informative. Classification of missense variants into deleterious/high risk or neutral/low clinical significance is essential to identify individuals at risk.

Objective: To investigate a panel of missense variants.

Methods and results: The panel was investigated in a comprehensive framework that included (1) a functional assay based on transcription activation; (2) segregation analysis and a method of using incomplete pedigree data to calculate the odds of causality; (3) a method based on interspecific sequence variation. It was shown that the transcriptional activation assay could be used as a test to characterise mutations in the carboxy-terminus region of BRCA1 encompassing residues 1396–1863. Thirteen missense variants (H1402Y, L1407P, H1421Y, S1512I, M1628T, M1628V, T1685I, G1706A, T1720A, A1752P, G1788V, V1809F, and W1837R) were specifically investigated.

Conclusions: While individual classification schemes for BRCA1 alleles still present limitations, a combination of several methods provides a more powerful way of identifying variants that are causally linked to a high risk of breast and ovarian cancer. The framework presented here brings these variants nearer to clinical applicability.
isolated and ligated to a similarly digested pGBT9 11B24.

(aa 1–323) was digested with full length, a PCR fragment corresponding to exons 2–11B fragment, generating a pGBT9 (aa 302–1863). To obtain the and the end of BRCA1 coding region. Subsequently, I and isolating a 6.1 kb fragment containing the vector (13–21 only), or

As well as to identify the strengths and limitations of current types constructs produced in a methylation competent bacterial strain, and amplification was carried out using Pfu polymerase. L1407P (L1407P-U, 5′ CTGATCAAAGCCCGAGCA GG 3′; L1407P-L, 5′ CCTCTGAGGCGGTGTCAGCAG 3′); G1706A (G1706AF, 5′ GACAGTGGATATTTTTCTGACAGTGGCGG GGAATGG 3′; G1706AR, 5′ CATTTCGGCCCGGCAATTC TCGAGGATATTTCTGACAG 3′); UX13; H1421Y, 5′ GCCTGAGGCTTTTCTCAGCTGCTG 3′; 24ENDT); S1512I 5′ CACGAGTCTGACAGTGCGG 3′; UX13); W1837R 5′ GCCTGAGGCTTTTCTCAGCTGCTG 3′; 24ENDT); P1614S 5′ CACGAGTCTGACAGTGCGG 3′; UX13); M1628V 5′ CACGAGTCTGACAGTGCGG 3′; UX13).

Methods

Constructs

Wild type GAL4 DNA binding domain (DBD) fusion construct aa 1560–1863 of human BRCA1 in pGBT9 (Clontech) was previously described. 4 The following wild type BRCA1 fragments were amplified by polymerase chain reaction (PCR) using the plasmid pcBRCA1-385 (a gift from Michael Erdos, National Human Genome Research Institute) as a template and the following nucleotide primers: T1700A (T1700A-U, 5′ CACGAGTCTGACAGTGCGG 3′; UX13); W1837R 5′ GCCTGAGGCTTTTCTCAGCTGCTG 3′; 24ENDT); P1614S 5′ CACGAGTCTGACAGTGCGG 3′; UX13); M1628V 5′ CACGAGTCTGACAGTGCGG 3′; UX13).

Two Saccharomyces cerevisiae strains were used: EGY48 [MATa, ura3, trpl, his3, 6 lexA operator-LEU2] and SFY526 [MATa, ura 3-52, his3-200, ade 2-101, lys s-801, trp 1-901, leu 2-3, 112, can2, gal 4-542, gal 8-538, URA3: GAL1-lacZ].27 SFY526 cells contain a lacZ reporter gene under the control of GAL1 UAS, which is recognised by GAL4 DNA binding domain (DBD). EGY48 cells were transformed with plasmid reporters

ATACATCAATATTTTTGCCGAGCAGAAGGAG 3′). Mutations L1407P, A1752P, and G1706A were introduced by the Quickchange (Stratagene) method according to the manufacturer’s instruction. The following primers containing the alteration of interest were used for PCR involving the wild type constructs produced in a methylation competent bacterial strain, and amplification was carried out using Pfu polymerase. L1407P (L1407P-U, 5′ CTGATCAAAGCCCGAGCA GG 3′; L1407P-L, 5′ CCTCTGAGGCGGTGTCAGCAG 3′); G1706A (G1706AF, 5′ GACAGTGGATATTTTTCTGACAGTGGCGG GGAATGG 3′; G1706AR, 5′ CATTTCGGCCCGGCAATTC TCGAGGATATTTCTGACAG 3′); UX13; H1421Y, 5′ GCCTGAGGCTTTTCTCAGCTGCTG 3′; 24ENDT); S1512I 5′ CACGAGTCTGACAGTGCGG 3′; UX13); W1837R 5′ GCCTGAGGCTTTTCTCAGCTGCTG 3′; 24ENDT); P1614S 5′ CACGAGTCTGACAGTGCGG 3′; UX13); M1628V 5′ CACGAGTCTGACAGTGCGG 3′; UX13).

Transcription assay in yeast

Two Saccharomyces cerevisiae strains were used: EGY48 [MATa, ura3, trpl, his3, 6 lexA operator-LEU2] and SFY526 [MATa, ura 3-52, his3-200, ade 2-101, lys s-801, trp 1-901, leu 2-3, 112, can2, gal 4-542, gal 8-538, URA3: GAL1-lacZ].27 SFY526 cells contain a lacZ reporter gene under the control of GAL1 UAS, which is recognised by GAL4 DNA binding domain (DBD). EGY48 cells were transformed with plasmid reporters
T1720A and V1809F were not assessed.

phoresis (DGGE) with the following frequencies: H1402Y variants were assessed by denaturing gradient gel electrophoresis. All were at a frequency of 0/500. The remaining without cancer of varying ages (18–40 years) and ethnic groups. All were at a frequency of 0/500. The remaining variants were assessed by denaturing gradient gel electrophoresis (DGGE) with the following frequencies: H1402Y (0/500), L1407P (0/500), H1421Y (0/500), S1512I (6/500), S1613G (260/500), M1628V (0/500), M1628T (0/500), T1650I (0/500), W1837R (0/500), and Y1853X (0/500). Variants T1720A and V1809F were not assessed.

**Transcription assay in mammalian cells**

We used pG5Luc, which contains a firefly luciferase gene under the control of five GAL4 binding sites, as a reporter for the assay. Transfections were normalised with an internal control phGR-TK (Promega), which contains a Renilla luciferase gene under a constitutive TK basal promoter using a dual luciferase system. Human 293T cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 5% calf serum and plated in 24-well plates the day before transfection. Transfections were done in triplicate using Fugene 6 (Roche) and harvested 24 hours post-transfection. Cells were lysed in RIPA buffer (150 mM NaCl, 10 mM Tris-HCl pH 7.4, 5 mM EDTA, 0.1% sodium dodecyl sulphate, 1% Triton X-100, 0.1% sodium deoxycholate). The blots were incubated with a-β-gAL4 DBD monoclonal antibody (Clontech). Lysates were cleared and samples were separated on 10% SDS-PAGE; equal amounts of protein were loaded for every sample. Gels were electroblotted on a wet apparatus to a polyvinylidene difluoride (PVDF) membrane and probed with an a- LexA DBD monoclonal antibody (Clontech).

Our laboratory has completed the analysis of 27% of the existing unclassified variants (32/117) in the C-terminus of BRCA1 (residues 1560–1863). To validate the assay we have used (a) all the unambiguously classified missense variants, and (b) all other variants for which there are strong (but not definitive) clinical data. Using the set of variants in (a), the assay correctly classified the four variants that can be classified unambiguously as deleterious (A1708E, R1699W, M1775R) or benign (S1613G) based on clinical data. Using the set of variants in (b), the assay correctly classified all nine other variants with strong supporting clinical evidence for classification. These results suggest a high sensitivity and specificity for this assay.

**RESULTS**

**Frequency in control populations**

Six variants (G1706A, A1708E, A1752P, M1775R, G1788V, and W1837R) were assessed using PCR/LDR followed by assessment in a DNA microarray in 500 healthy women without cancer of varying ages (18–40 years) and ethnic groups. All were at a frequency of 0/500. The remaining variants were assessed by denaturing gradient gel electrophoresis (DGGE) with the following frequencies: H1402Y (0/500), L1407P (0/500), H1421Y (0/500), S1512I (6/500), S1613G (260/500), M1628V (0/500), M1628T (0/500), T1650I (0/500), W1837R (0/500), and Y1853X (0/500). Variants T1720A and V1809F were not assessed.

**Activation of transcription**

Regions of BRCA1 that contribute to its transcription activation function besides aa 1560–1863 might also be used in a transcription based functional assays to classify missense variants. In order to determine their contribution we quantitatively assessed activation of a β-galactosidase reporter gene under the control of a GAL4 responsive promoter by a series of GAL4DBD:BRCA1 fusion constructs in yeast (fig 1A). These constructs were designed to test systematically the contribution of exons 13 to 24 to activation.

While a construct including aa 1455–1863 did not show activity that was significantly higher than aa 1560–1863, a construct containing aa 1396–1863 had an activity that was markedly higher (fig 1B). The results in a mammalian expression system confirmed those obtained in yeast, with construct aa 1396–1863 showing the highest activity (fig 1C). In this case, however, the contribution of aa 1455–1559 is less clear, but this may reflect instability of the aa 1455–1863 construct in mammalian cells. We can detect expression of this construct when using a polyclonal antibody (fig 1D, second lane), but it is not recognised by a monoclonal antibody raised against a similar epitope (compare second lane in fig 1D, top and bottom panel). We were unable to obtain significant levels of expression of the GAL4DBD full length protein in 293T cells, even after several attempts.

**BRCT domain alone is not capable of activating transcription**

Previous experiments indicated that the BRCT-C repeat alone could activate transcription when fused to a heterologous DBD. Although activity was abolished by disruption of the BRCT-C repeat, it was still possible that the first domain could show residual activity. To test for this, we made a GAL4 fusion construct aa 1396–1778, which includes BRCT-N (aa 1653–1736) but not BRCT-C (aa 1760–1855). Sequences contained in aa 1396–1559 were defined as the strongest auxiliary activating region in BRCA1 (see above), providing the most favourable context to demonstrate any residual activity. This construct did not show any significant activation (not shown), indicating that this region can collaborate to augment activity but cannot act alone. Although there is a correlation of negative charge and transcription activation, charge does not seem to be the only determinant (fig 1). The fragment aa 1560–1863 is less negatively charged than the aa 1396–1778 fragment, yet the former is able to activate transcription while the latter is not. In conclusion, sequences outside the BRCT domains confer higher activity to BRCA1 but cannot act alone. The construct containing exons 13–24 (aa 1396–1863) showed the highest transcription activation (15-fold activation ability over full length BRCA1) being the most sensitive to detect differences in transcription activation and it was therefore chosen as the backbone in which to introduce the sequence variants for the transcription activation assay.

**Functional analysis of missense variants**

The location of the 13 missense variants studied as well as the negative and positive controls are indicated by arrows in fig 2A. Seven variants lie in the BRCT domains. Six of the variants lie upstream of the BRCT domains, three of which lie within the putative coiled coil domain (fig 2A). Three known BRCT deleterious/high risk variants—A1708E, M1775R, and Y1853X—were used as negative (that is, loss of function) controls, and S1613G (a common neutral polymorphism) and wild type BRCA1 (aa 1396–1863) were employed as positive controls. Results show that both in yeast and mammalian cells the three negative controls located in the BRCT domain lost most of transcription activation function consistent with a loss of function mutation, whereas the positive control S1613G had an activity equal to or higher than the wild type, as observed previously (fig 2B and 2C). Seven unclassified missense variants in the BRCT domains (T1650I, G1706A, T1720A, A1752P, G1788V, V1809F, and W1837R) were then tested. Variants T1650I, A1752P, G1788V, V1809F, and W1837R showed greatly decreased transcription activation
levels (at least <50%) both in yeast and mammalian cells, comparable with the known mutant controls and consistent with their classification as deleterious/high risk variants (fig 2B and 2C).

Variants G1706A and T1720A showed slightly reduced transcription activation levels in yeast cells, at 64% and 74%, respectively, of the wild type control. Interestingly, whereas T1720A had activity comparable to wild type in mammalian cells, G1706A showed a markedly reduced activity. The intermediate results for these mutants suggest that they may represent moderate rather than high risk variants.

Six additional variants (H1402Y, L1407P, H1421Y, S1512I, M1628T, and M1628V) in locations outside the BRCT domains were also investigated for their effect on transcription. Three of the variants were located in a region in which a putative coiled coil domain has been predicted to form (fig 2A). Variant L1407P showed significantly reduced transcription activation levels consistent with a high risk mutation (fig 2B, 2C). Variants H1402Y, H1421Y, and S1512I showed transcription activation levels equal to or higher than wild type BRCA1, suggesting that they do not represent high risk variants and are likely to have low clinical significance.

In yeast cells, protein levels were slightly variable in three independent clones. Most variants displayed levels comparable to wild type, with the exception of Y1853X and T1685I, which showed markedly reduced levels suggesting that protein instability might be the underlying cause of loss of function. In mammalian cells, some variants (S1512I, V1809F, and W1837R) had markedly reduced levels. However, no loss of function variant showed consistently reduced levels in yeast and mammalian cells, suggesting that even when expressed at higher levels they were unable to activate transcription (fig 2D).

**Pedigree analysis**

In order to obtain additional information to classify the missense variants we applied a recently developed full likelihood method for the evaluation of causality from family data. For the analysis of co-segregation we assumed an allele frequency of the variant of 0.0001 and a penetrance model with separate age specific risks of breast and ovarian cancer for BRCA1 based on meta-analysis estimates. We obtained six pedigrees for five variants (M1628T, G1706A, T1720A, V1809F, and W1837R) (fig 3). For M1628T we obtained odds against causality of 10.4:1, consistent with the data obtained in the functional assay. For G1706A we obtained odds against causality of 1.3:1. This rather uninformative result reflects the fact that this large pedigree with multiple cases typed had one case diagnosed at age 53 that did not carry the variant. This result may also reflect the
fact that G1706A may be a moderate rather than a high risk variant. For variant V1809F the odds in favour of causality were 7.3:1, consistent with the functional test, suggesting that it is a high risk variant. Two pedigrees were analysed for the T1720A variant generating combined odds against causality of 355:1. This result is also consistent with the functional data and suggests that T1720A represents a neutral/low clinical significance variant. For variant W1837R we obtained odds of 4:1 against causality, which contradicts our functional data.

**Analysis of interspecific sequence variation**

In order to determine further the likelihood that a particular variant may or may not represent a high risk variant we also analysed the amino acid substitution using a modified Grantham matrix, adapted for BRCA1.23 These results are shown in table 1. The classification based on interspecific sequence variation confirms our choice of controls, with S1613G being classified as neutral and M1775R, A1708E, and Y1853X being classified as deleterious. It also confirms our functional results for H1402Y, L1407P, T1685I, G1706A, G1788V, and W1837R. Variant M1628V, however, was classified as a neutral/low risk variant in contradiction of our functional results. The remaining variants could not be classified by this method.

**Co-occurrence with deleterious mutations**

Homozygous disruption of Brca1 in mouse resulted in embryonic lethality (reviewed by Brodie and Deng). In addition, there is a deficit from expected numbers of BRCA1 homozygotes and compound heterozygotes for deleterious mutations among individuals with the founder mutations 185delAG and 5382insC.44 This led to the notion that if an unknown variant co-occurs with a known deleterious mutation it is unlikely that this variant is a high risk one. Co-occurrence data relative to a set of 40 000 individuals (kindly provided Amie Deffenbaugh, Myriad Genetics Laboratories Inc) are listed in table 1. Variants H1402Y, S1512, and M1628T co-occur with a deleterious mutation and are therefore unlikely to represent high risk variants, a result supported by the functional assays.

**DISCUSSION**

In order to provide a more informative risk assessment for individuals carrying a mutation in BRCA1 we used several approaches, including association studies and segregation

---

**Figure 2** Functional analysis of missense variants in BRCA1.

(A) Location of variants (blue), negative and positive controls (red and green, respectively). Grey boxes, BRCT domains; DBD, GAL4 DNA binding domain; blue box, putative coiled-coil domain. (B) Quantitative assay in yeast. (C) Quantitative assays in mammalian cells. (D) Protein levels were determined by western blots in yeast (upper panel) and mammalian cells (lower panel).
analysis. However, the clinical relevance of missense variants has been particularly elusive because of their low frequency, making it difficult to conduct meaningful population based studies. Several lines of investigation must be considered in the classification of a BRCA1 variant into deleterious/high risk or neutral/low clinical significance. Segregation of the variant in the status, but the frequencies of variants differ considerably between ethnic groups. Segregation of the variant in high risk individuals (affected by breast or ovarian cancer and with a family history of breast or ovarian cancer) compared with controls can provide clues as to its status, but the frequencies of variants differ considerably between ethnic groups. Segregation of the variant in the family members affected by the disease may be a strong indicator that a variant is deleterious except if it is in linkage disequilibrium with another mutation, as observed in some ethnic groups. Additional approaches have relied on sequence comparisons or on functional tests which include specific assays such as transcription activation, or broader phenotypes such as the generation of a yeast small colony phenotype or induction of apoptosis in cultured cells.

One method of classification of a BRCA1 variant is the transcription functional assay. We have previously shown that alleles containing neutral polymorphisms retained wild type activity in transcription. Several lines of evidence have pointed to a physiological role of BRCA1 in transcription, although its exact biochemical function is unclear. However, regardless of whether or not BRCA1 acts as a transcription activator in vivo, we have proposed that a transcription assay using a heterologous DNA binding domain fusion and a reporter gene serves as a monitor of the integrity of the C-terminal region of BRCA1. Because this region is essential for the tumour suppressive function of BRCA1, the transcription assay is able to generate information about the impact of missense changes. Previously, this assay was only applicable to variants in the BRCT domain (exons 16–24). Here we show that regions adjacent to the BRCT domains contribute to full activity in transcription, allowing us to extend our analysis to encompass exons 13–24. Once it was verified that the extended assay assigned positive and negative controls correctly, seven missense variants in the BRCT domain and six variants outside the BRCT domain were tested (fig 2).

Seven of the variants caused a dramatic loss of the transcription activation function (L1407P, M1628V, T1685I, A1752P, G1788V, V1809F, and W1837R), similar to known high risk mutation controls, suggesting that they may constitute deleterious/high risk variants (fig 2B and 2C; table 1). Four of the variants (H1402Y, H1421Y, S1512I, and M1628T) showed transcription activation similar to or greater than the wild type BRCA1, suggesting they are probably neutral/low clinical significance variants. The two remaining variants had intermediate results. G1706A showed a slightly reduced activity in yeast but a markedly reduced activity in mammalian cells. Variant T1720A had a slightly reduced activity in yeast and but activity comparable to wild type BRCA1 in mammalian cells. Variant T1720A had a slightly reduced activity in yeast and but activity comparable to wild type BRCA1 in mammalian cells. Based on the results obtained we would tentatively classify T1720A as a neutral/low clinical significance variant. At this point we cannot classify variant G1706A.

We then carried out an analysis using interspecific variation, pedigree analysis, and co-occurrence data (table 1). Of the seven variants for which the method based on interspecific variation was able to reach a conclusion, the data confirmed the classification based on our functional tests in six cases (L1407P, H1402Y, T1685I, G1706A, G1788V, and W1837R) but presented a contradiction for variant M1628V. The pedigree analysis confirmed our results for
The conclusion can be drawn for variants that have very low available information is not enough to classify it. While no results for G1706A suggested again that the analysis for W1837R contradicted all the other methods, allele frequency comparable in control and in breast-ovarian cancer cases; clinical data favour classification as benign polymorphism. Interestingly, results for G1706A suggested again that the analysis for W1837R contradicted all the other methods, allele frequency comparable in control and in breast-ovarian cancer cases; clinical data favour classification as benign polymorphism. Commonly found in the Japanese group used as controls; clinical data favour classification as benign polymorphism. Found in a case with bilateral breast cancer at 41/46 y; her mother was disease-free, but grandmother and grandfather’s sister had breast cancer at 55 and 85 y, respectively.

<table>
<thead>
<tr>
<th>Exon</th>
<th>Mutation</th>
<th>Nucleotide change</th>
<th>Allowed residues†</th>
<th>TXN°</th>
<th>IV°</th>
<th>PDG‡</th>
<th>PS**</th>
<th>ST††</th>
<th>BIC‡‡</th>
<th>CO$^\circ$</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>13</td>
<td>H1402Y</td>
<td>C4323T</td>
<td>HDYNK</td>
<td>○</td>
<td>○</td>
<td>nd</td>
<td>na</td>
<td>na</td>
<td>1</td>
<td>1</td>
<td>Reduces the probability to form coiled coil structure from 0.936 to 0.532</td>
</tr>
<tr>
<td>13</td>
<td>L1407P</td>
<td>T4339C</td>
<td>L</td>
<td>●</td>
<td>?</td>
<td>nd</td>
<td>na</td>
<td>na</td>
<td>0</td>
<td>0</td>
<td>Conserved stretch; reduces the probability to form coiled coil structure from 0.936 to 0.037</td>
</tr>
<tr>
<td>13</td>
<td>H1421Y</td>
<td>C4380T</td>
<td>HRK</td>
<td>○</td>
<td>?</td>
<td>nd</td>
<td>na</td>
<td>na</td>
<td>2</td>
<td>0</td>
<td>Reduces the probability to form coiled coil structure from 0.936 to 0.650</td>
</tr>
<tr>
<td>15</td>
<td>S1512I</td>
<td>C4380T</td>
<td>HDYNK</td>
<td>○</td>
<td>?</td>
<td>nd</td>
<td>na</td>
<td>na</td>
<td>50</td>
<td>14</td>
<td>Allele frequency comparable in control and in breast-ovarian cancer cases; clinical data favour classification as benign polymorphism</td>
</tr>
<tr>
<td>16</td>
<td>S1613G</td>
<td>A4956G</td>
<td>SNF</td>
<td>○</td>
<td>○</td>
<td>nd</td>
<td>na</td>
<td>na</td>
<td>33</td>
<td>371</td>
<td>Allele frequency comparable in control and in breast-ovarian cancer cases; clinical data favour classification as benign polymorphism</td>
</tr>
<tr>
<td>16</td>
<td>M1628V</td>
<td>A4956G</td>
<td>MVSR</td>
<td>●</td>
<td>○</td>
<td>nd</td>
<td>na</td>
<td>na</td>
<td>4</td>
<td>0</td>
<td>Allele frequency comparable in control and in breast-ovarian cancer cases; clinical data favour classification as benign polymorphism</td>
</tr>
<tr>
<td>17</td>
<td>T1689S</td>
<td>C5173T</td>
<td>T</td>
<td>●</td>
<td>●</td>
<td>nd</td>
<td>nd</td>
<td>●</td>
<td>2</td>
<td>0</td>
<td>Known unfolding mutation; no detectable activity in transcription assays or small colony phenotype test.</td>
</tr>
<tr>
<td>18</td>
<td>G1706A</td>
<td>G5236C</td>
<td>MVSR</td>
<td>○</td>
<td>?</td>
<td>na</td>
<td>na</td>
<td>39</td>
<td>0</td>
<td>Known unfolding mutation; no detectable activity in transcription assays or small colony phenotype test.</td>
<td></td>
</tr>
<tr>
<td>18</td>
<td>M1628T</td>
<td>T5002C</td>
<td>MVSR</td>
<td>○</td>
<td>?</td>
<td>na</td>
<td>na</td>
<td>70</td>
<td>4</td>
<td>Known unfolding mutation; no detectable activity in transcription assays or small colony phenotype test.</td>
<td></td>
</tr>
<tr>
<td>18</td>
<td>A1708E</td>
<td>C5242A</td>
<td>A</td>
<td>●</td>
<td>●</td>
<td>na</td>
<td>●</td>
<td>●</td>
<td>39</td>
<td>0</td>
<td>Known unfolding mutation; no detectable activity in transcription assays or small colony phenotype test.</td>
</tr>
<tr>
<td>19</td>
<td>T1720A</td>
<td>A5277G</td>
<td>TIVS</td>
<td>●</td>
<td>?</td>
<td>na</td>
<td>●</td>
<td>●</td>
<td>39</td>
<td>0</td>
<td>Known unfolding mutation; no detectable activity in transcription assays or small colony phenotype test.</td>
</tr>
<tr>
<td>20</td>
<td>A1752P</td>
<td>G5373C</td>
<td>AS</td>
<td>●</td>
<td>?</td>
<td>nd</td>
<td>●</td>
<td>●</td>
<td>39</td>
<td>0</td>
<td>Known unfolding mutation; no detectable activity in transcription assays or small colony phenotype test.</td>
</tr>
<tr>
<td>21</td>
<td>M1775R</td>
<td>T5443G</td>
<td>M</td>
<td>●</td>
<td>●</td>
<td>na</td>
<td>●</td>
<td>●</td>
<td>23</td>
<td>0</td>
<td>Known unfolding mutation; no detectable activity in transcription assays or small colony phenotype test.</td>
</tr>
<tr>
<td>22</td>
<td>G1788V</td>
<td>G5482T</td>
<td>G</td>
<td>●</td>
<td>●</td>
<td>nd</td>
<td>●</td>
<td>●</td>
<td>15</td>
<td>0</td>
<td>Known unfolding mutation; no detectable activity in transcription assays or small colony phenotype test.</td>
</tr>
<tr>
<td>22</td>
<td>V1809F</td>
<td>G5544T</td>
<td>VIL</td>
<td>●</td>
<td>●</td>
<td>□</td>
<td>●</td>
<td>●</td>
<td>40</td>
<td>0</td>
<td>Known unfolding mutation; no detectable activity in transcription assays or small colony phenotype test.</td>
</tr>
<tr>
<td>24</td>
<td>W1837R</td>
<td>T5628C</td>
<td>W</td>
<td>●</td>
<td>●</td>
<td>□</td>
<td>●</td>
<td>□</td>
<td>5</td>
<td>0</td>
<td>Known unfolding mutation; no detectable activity in transcription assays or small colony phenotype test.</td>
</tr>
<tr>
<td>24</td>
<td>Y1853X</td>
<td>C5677A/G</td>
<td>Y</td>
<td>●</td>
<td>●</td>
<td>na</td>
<td>●</td>
<td>●</td>
<td>10</td>
<td>0</td>
<td>Known unfolding mutation; no detectable activity in transcription assays or small colony phenotype test.</td>
</tr>
</tbody>
</table>

*Nucleotide numbering corresponds to human BRCA1 cDNA deposited in GenBank accession number U14680.
†Amino acid residues present at the same position in the BRCA1 orthologs. The multiple sequence alignment of orthologous BRCA1 BRCT domains from eight species, including Homo sapiens (GenBank accession number U14680), Pan troglodytes (AF207822), Mus musculus (U68174), Rattus norvegicus (AF036760), Gallus gallus (AF355273), Canis familiaris (US0709), Bos Taurus (AY077732), Xenopus laevis (AF146868), and Tetraodon nigroviridis (AY428536), was obtained by using program MegAlign (Clustal W).
‡Interspecific variation.
§Pedigree analysis.
**Protease sensitivity; data from Williams et al.12
††Structure based prediction; data from Mirkovic et al.14
‡‡Number of times this variant has been reported to the BIC database as of August 2004.
§§Number of times this variant has been observed co-occurring with a known deleterious BRCA1 mutation in 40,000 samples (Myriad Genetics Laboratories).
*$^*$According to prediction by the Pairscoil scoring form (http://pairscoil.lcs.mit.edu/cgi-bin/pairscoil).
○, neutral/low clinical relevance; ↘, moderate to low risk variant; ●, deleterious/high risk variant; nd, not determined; na, not applicable; ?, unclassified.

Table 1: Comprehensive analysis of BRCA1 variants

Three of the four variants analysed. Results from pedigree analysis for W1837R contradicted all the other methods, although the odds against causality were rather small. Interestingly, results for G1706A suggested again that the available information is not enough to classify it. While no conclusion can be drawn for variants that have very low frequency and are not found to co-occur with a deleterious mutation (for example, L1407P and H1421Y), co-occurrence data indicated that H1402Y, S1512, and M1628T do not represent high risk variants, confirming the functional assay results. In order to further cross validate our analysis we compared it with results from three published methods to classify variants in the BRCT domain (table 1). The first method is
Classification of BRCA1 missense variants of unknown clinical significance

V Dapic,* B Tice, A N A Monteiro, Laboratory of Molecular Oncology, Strong Cancer Prevention Center, New York, USA
R Favis, F Barany, Department of Microbiology, Joan and Sanford I. Weill Medical College of Cornell University, New York, NY 10021, USA
S Monoukian, P Radice, Department of Experimental Oncology, Istituto Nazionale Tumori, 20133 Milan, Italy and IARC Institute of Molecular Oncology, 20139 Milan, Italy
R B van der Luijt, B P M van Nesselrooij, Department of Medical Genetics, University Medical Centre Utrecht, 3508 AB Utrecht, Netherlands
G Chenevix-Trench, Cancer and Cell Biology Division, Queensland Institute of Medical Research, Queensland, Australia
kConFab, Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer; Peter MacCallum Cancer Institute, East Melbourne, Australia
T Caldes, M de La Hoy, Laboratory of Molecular Oncology, Hospital Clinico San Carlos, Madrid, Spain
S Lindquist, John F Kennedy Institute, Glostrup, Denmark
S V Tavtigian, Cancer Susceptibility Unit, International Agency for Research on Cancer, Lyon, France
D Goldgar, Genetic Epidemiology Unit, International Agency for Research on Cancer
A á Borg, Department of Oncology, University Hospital, Lund, Sweden

*These authors contributed equally to this work

Conflicts of interest: none declared

REFERENCES

www.jmedgenet.com


